In the last 12 months, insiders at CytomX Therapeutics, Inc. ($CTMX) filed 117 transactions with the SEC: 0 open-market purchases totaling $0 and 24 sales totaling $2,091,635. Net insider sentiment: net selling.
CytomX Therapeutics, Inc. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- McCarthy Sean A. (CEO) — 23 transactions totaling $1,629,994
- BELVIN MARCIA (SVP, Chief Scientific Officer) — 24 transactions totaling $283,118
- Ogden Christopher (Chief Financial Officer) — 19 transactions totaling $165,054
- Chu Yu-Waye (Chief Medical Officer) — 13 transactions totaling $139,086
- ROWLAND LLOYD A (General Counsel) — 8 transactions totaling $22,237
View all SEC Filings for CytomX Therapeutics, Inc. (CTMX).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 17, 2026 | BELVIN MARCIA | SVP, Chief Scientific Officer | S | Common Stock | 31492 | $6.42 | 300,760.0000 | 169,435,395 | 9.48% | 0.02% |
| March 17, 2026 | McCarthy Sean A. | CEO | S | Common Stock | 118969 | $6.42 | 1,172,080.0000 | 169,435,395 | 9.21% | 0.07% |
| March 17, 2026 | Chu Yu-Waye | Chief Medical Officer | S | Common Stock | 21279 | $6.42 | 189,446.0000 | 169,435,395 | 10.10% | 0.01% |
| March 17, 2026 | Ogden Christopher | Chief Financial Officer | S | Common Stock | 19323 | $6.42 | 296,948.0000 | 169,435,395 | 6.11% | 0.01% |
| Feb. 2, 2026 | McCarthy Sean A. | CEO | A | Stock Option (Right to Buy) | 980000 | $0.00 | 980,000.0000 | 169,435,395 | 9999.99% | 0.58% |
| Feb. 2, 2026 | McCarthy Sean A. | CEO | A | Common Stock | 210000 | $0.00 | 1,291,049.0000 | 169,435,395 | 19.43% | 0.12% |
| Feb. 2, 2026 | Ogden Christopher | Chief Financial Officer | A | Stock Option (Right to Buy) | 325000 | $0.00 | 325,000.0000 | 169,435,395 | 9999.99% | 0.19% |
| Feb. 2, 2026 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 250000 | $0.00 | 250,000.0000 | 169,435,395 | 9999.99% | 0.15% |
| Feb. 2, 2026 | Ogden Christopher | Chief Financial Officer | A | Common Stock | 90000 | $0.00 | 316,271.0000 | 169,435,395 | 39.78% | 0.05% |
| Feb. 2, 2026 | Lester Rachael | Chief Business Officer | A | Common Stock | 20000 | $0.00 | 20,000.0000 | 169,435,395 | 9999.99% | 0.01% |
| Feb. 2, 2026 | Lester Rachael | Chief Business Officer | A | Stock Option (Right to Buy) | 50000 | $0.00 | 50,000.0000 | 169,435,395 | 9999.99% | 0.03% |
| Feb. 2, 2026 | Lester Rachael | Chief Business Officer | A | Performance Stock Units (PSUs) | 50000 | $0.00 | 50,000.0000 | 169,435,395 | 9999.99% | 0.03% |
| Feb. 2, 2026 | Chu Yu-Waye | Chief Medical Officer | A | Common Stock | 75000 | $0.00 | 210,725.0000 | 169,435,395 | 55.26% | 0.04% |
| Feb. 2, 2026 | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 300000 | $0.00 | 300,000.0000 | 169,435,395 | 9999.99% | 0.18% |
| Feb. 2, 2026 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 60000 | $0.00 | 332,252.0000 | 169,435,395 | 22.04% | 0.04% |
| Nov. 6, 2025 | McCarthy Sean A. | CEO | S | Class A Common Stock | 101793 | $4.54 | 1,081,049.0000 | 169,435,395 | 8.61% | 0.06% |
| Oct. 20, 2025 | Lester Rachael | Chief Business Officer | A | Stock Option (Right to Buy) | 650000 | $0.00 | 650,000.0000 | 80,099,889 | 9999.99% | 0.81% |
| Sept. 26, 2025 | Chu Yu-Waye | Chief Medical Officer | A | Performance Stock Units (PSUs) | 43750 | $0.00 | 43,750.0000 | 80,099,889 | 9999.99% | 0.05% |
| Sept. 26, 2025 | McCarthy Sean A. | CEO | A | Performance Stock Units (PSUs) | 285000 | $0.00 | 285,000.0000 | 80,099,889 | 9999.99% | 0.36% |
| Sept. 26, 2025 | McCarthy Sean A. | CEO | A | Stock Option (Right to Buy) | 570000 | $0.00 | 570,000.0000 | 80,099,889 | 9999.99% | 0.71% |
| Sept. 26, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Performance Stock Units (PSUs) | 18150 | $0.00 | 18,150.0000 | 80,099,889 | 9999.99% | 0.02% |
| Sept. 26, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 36300 | $0.00 | 36,300.0000 | 80,099,889 | 9999.99% | 0.05% |
| Sept. 26, 2025 | Ogden Christopher | Chief Financial Officer | A | Performance Stock Units (PSUs) | 39150 | $0.00 | 39,150.0000 | 80,099,889 | 9999.99% | 0.05% |
| Sept. 26, 2025 | Ogden Christopher | Chief Financial Officer | A | Stock Option (Right to Buy) | 78250 | $0.00 | 78,250.0000 | 80,099,889 | 9999.99% | 0.10% |
| Sept. 26, 2025 | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 87500 | $0.00 | 87,500.0000 | 80,099,889 | 9999.99% | 0.11% |
| June 16, 2025 | Ogden Christopher | Chief Financial Officer | S | Common Stock | 10614 | $2.69 | 226,271.0000 | 80,099,889 | 4.48% | 0.01% |
| June 13, 2025 | Ogden Christopher | Chief Financial Officer | M | Common Stock | 37500 | $0.00 | 236,885.0000 | 80,099,889 | 18.81% | 0.05% |
| June 13, 2025 | McCarthy Sean A. | CEO | M | Performance Stock Units | 150000 | $0.00 | 0.0000 | 80,099,889 | 100.00% | 0.19% |
| June 16, 2025 | McCarthy Sean A. | CEO | S | Common Stock | 55511 | $2.69 | 1,182,842.0000 | 80,099,889 | 4.48% | 0.07% |
| June 13, 2025 | McCarthy Sean A. | CEO | M | Common Stock | 150000 | $0.00 | 1,238,353.0000 | 80,099,889 | 13.78% | 0.19% |
| June 13, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | M | Performance Stock Units | 37500 | $0.00 | 0.0000 | 80,099,889 | 100.00% | 0.05% |
| June 16, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | S | Common Stock | 13884 | $2.69 | 272,252.0000 | 80,099,889 | 4.85% | 0.02% |
| June 13, 2025 | Ogden Christopher | Chief Financial Officer | S | Common Stock | 1641 | $2.95 | 199,385.0000 | 80,099,889 | 0.82% | 0.00% |
| June 13, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | M | Common Stock | 37500 | $0.00 | 286,136.0000 | 80,099,889 | 15.08% | 0.05% |
| June 13, 2025 | Ogden Christopher | Chief Financial Officer | M | Performance Stock Units | 37500 | $0.00 | 0.0000 | 80,099,889 | 100.00% | 0.05% |
| June 11, 2025 | Jones Elaine V | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 80,099,889 | 9999.99% | 0.05% |
| June 11, 2025 | Su Zhen | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 80,099,889 | 9999.99% | 0.05% |
| June 11, 2025 | Young Matthew P. | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 80,099,889 | 9999.99% | 0.05% |
| June 11, 2025 | Mohindru Mani | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 80,099,889 | 9999.99% | 0.05% |
| June 11, 2025 | Meyers James R | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 80,099,889 | 9999.99% | 0.05% |
| June 11, 2025 | Gilbert Halley E | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 80,099,889 | 9999.99% | 0.05% |
| June 11, 2025 | Ashworth Alan | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 80,099,889 | 9999.99% | 0.05% |
| March 18, 2025 | Ogden Christopher | Chief Financial Officer | S | Common Stock | 8551 | $0.60 | 201,026.0000 | 80,099,889 | 4.08% | 0.01% |
| March 18, 2025 | Chu Yu-Waye | Chief Medical Officer | S | Common Stock | 4025 | $0.60 | 135,725.0000 | 80,099,889 | 2.88% | 0.01% |
| March 18, 2025 | ROWLAND LLOYD A | General Counsel | S | Common Stock | 10203 | $0.60 | 120,594.0000 | 80,099,889 | 7.80% | 0.01% |
| March 18, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | S | Common Stock | 19512 | $0.60 | 248,636.0000 | 80,099,889 | 7.28% | 0.02% |
| March 18, 2025 | McCarthy Sean A. | CEO | S | Common Stock | 37656 | $0.60 | 1,088,353.0000 | 80,099,889 | 3.34% | 0.05% |
| Feb. 4, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 115000 | $0.00 | 115,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 35000 | $0.00 | 210,648.0000 | 0 | 19.93% | 0.00% |
| Feb. 4, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 57500 | $0.00 | 268,148.0000 | 0 | 27.30% | 0.00% |
| Feb. 4, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 57500 | $0.00 | 263,148.0000 | 0 | 27.96% | 0.00% |
| Feb. 4, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 30000 | $0.00 | 205,648.0000 | 0 | 17.08% | 0.00% |
| Feb. 4, 2025 | Chu Yu-Waye | Chief Medical Officer | A | Common Stock | 56000 | $0.00 | 82,250.0000 | 0 | 213.33% | 0.00% |
| Feb. 4, 2025 | Chu Yu-Waye | Chief Medical Officer | A | Common Stock | 57500 | $0.00 | 139,750.0000 | 0 | 69.91% | 0.00% |
| Feb. 4, 2025 | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 238000 | $0.00 | 238,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 115000 | $0.00 | 115,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | Ogden Christopher | Chief Financial Officer | A | Common Stock | 57500 | $0.00 | 209,577.0000 | 0 | 37.81% | 0.00% |
| Feb. 4, 2025 | Ogden Christopher | Chief Financial Officer | A | Common Stock | 44000 | $0.00 | 152,077.0000 | 0 | 40.71% | 0.00% |
| Feb. 4, 2025 | Ogden Christopher | Chief Financial Officer | A | Stock Option (Right to Buy) | 225000 | $0.00 | 225,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | Ogden Christopher | Chief Financial Officer | A | Stock Option (Right to Buy) | 115000 | $0.00 | 115,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | McCarthy Sean A. | CEO | A | Common Stock | 180000 | $0.00 | 931,009.0000 | 0 | 23.97% | 0.00% |
| Feb. 4, 2025 | McCarthy Sean A. | CEO | A | Common Stock | 195000 | $0.00 | 1,126,009.0000 | 0 | 20.95% | 0.00% |
| Feb. 4, 2025 | McCarthy Sean A. | CEO | A | Stock Option (Right to Buy) | 800000 | $0.00 | 800,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | McCarthy Sean A. | CEO | A | Stock Option (Right to Buy) | 390000 | $0.00 | 390,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 115000 | $0.00 | 115,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 140000 | $0.00 | 140,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 20, 2024 | BELVIN MARCIA | SVP, Chief Scientific Officer | S | Common Stock | 4181 | $1.23 | 175,648.0000 | 0 | 2.32% | 0.00% |
| Aug. 20, 2024 | BELVIN MARCIA | SVP, Chief Scientific Officer | M | Performance Stock Units (PSUs) | 11250 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 20, 2024 | ROWLAND LLOYD A | General Counsel | M | Common Stock | 11250 | $0.00 | 134,978.0000 | 0 | 9.09% | 0.00% |
| Aug. 20, 2024 | ROWLAND LLOYD A | General Counsel | S | Common Stock | 4181 | $1.23 | 130,797.0000 | 0 | 3.10% | 0.00% |
| Aug. 20, 2024 | ROWLAND LLOYD A | General Counsel | M | Performance Stock Units (PSUs) | 11250 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 20, 2024 | Ogden Christopher | Chief Financial Officer | M | Common Stock | 6875 | $0.00 | 110,061.0000 | 0 | 6.66% | 0.00% |
| Aug. 20, 2024 | Ogden Christopher | Chief Financial Officer | S | Common Stock | 1984 | $1.23 | 108,077.0000 | 0 | 1.80% | 0.00% |
| Aug. 20, 2024 | Ogden Christopher | Chief Financial Officer | M | Performance Stock Units (PSUs) | 6875 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 20, 2024 | McCarthy Sean A. | CEO | M | Common Stock | 37500 | $0.00 | 764,907.0000 | 0 | 5.16% | 0.00% |
| Aug. 20, 2024 | McCarthy Sean A. | CEO | S | Common Stock | 13898 | $1.23 | 751,009.0000 | 0 | 1.82% | 0.00% |
| Aug. 20, 2024 | McCarthy Sean A. | CEO | M | Performance Stock Units (PSUs) | 37500 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 20, 2024 | BELVIN MARCIA | SVP, Chief Scientific Officer | M | Common Stock | 11250 | $0.00 | 179,829.0000 | 0 | 6.67% | 0.00% |
| Aug. 20, 2024 | Landau Jeffrey B | Chief Business Officer | M | Performance Stock Units (PSUs) | 11250 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 20, 2024 | Landau Jeffrey B | Chief Business Officer | S | Common Stock | 4181 | $1.23 | 126,736.0000 | 0 | 3.19% | 0.00% |
| Aug. 20, 2024 | Landau Jeffrey B | Chief Business Officer | M | Common Stock | 11250 | $0.00 | 130,917.0000 | 0 | 9.40% | 0.00% |
| June 12, 2024 | Ogden Christopher | Chief Financial Officer | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| June 12, 2024 | Ogden Christopher | Chief Financial Officer | A | Common Stock | 17500 | $0.00 | 103,186.0000 | 0 | 20.42% | 0.00% |
| May 15, 2024 | Ashworth Alan | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| May 15, 2024 | Gilbert Halley E | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| May 15, 2024 | Jones Elaine V | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| May 15, 2024 | Meyers James R | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| May 15, 2024 | Mohindru Mani | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| May 15, 2024 | Su Zhen | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| May 15, 2024 | Young Matthew P. | Not found | A | Stock Option (Right to Buy) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| March 26, 2024 | McCarthy Sean A. | CEO | M | Stock Option (Right to Buy) | 109768 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| March 26, 2024 | McCarthy Sean A. | CEO | M | Common Stock | 109768 | $1.57 | 727,407.0000 | 0 | 17.77% | 0.00% |
| March 20, 2024 | Su Zhen | Not found | A | Stock Option (Right to Buy) | 76000 | $0.00 | 76,000.0000 | 0 | 9999.99% | 0.00% |
| March 19, 2024 | ROWLAND LLOYD A | General Counsel | S | Common Stock | 5268 | $2.09 | 117,728.0000 | 0 | 4.28% | 0.00% |
| March 19, 2024 | Ogden Christopher | SVP, Finance and Accounting | S | Common Stock | 2971 | $2.09 | 85,686.0000 | 0 | 3.35% | 0.00% |
| March 19, 2024 | Landau Jeffrey B | Chief Business Officer | S | Common Stock | 6562 | $2.09 | 117,740.0000 | 0 | 5.28% | 0.00% |
| March 19, 2024 | BELVIN MARCIA | SVP, Chief Scientific Officer | S | Common Stock | 12795 | $2.09 | 168,579.0000 | 0 | 7.05% | 0.00% |
| March 19, 2024 | McCarthy Sean A. | CEO | S | Common Stock | 20223 | $2.09 | 617,639.0000 | 0 | 3.17% | 0.00% |
| Jan. 18, 2024 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 26250 | $0.00 | 181,374.0000 | 0 | 16.92% | 0.00% |
| Jan. 18, 2024 | Landau Jeffrey B | Chief Business Officer | A | Performance Stock Units (PSUs) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 122500 | $0.00 | 122,500.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Performance Stock Units (PSUs) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | Chu Yu-Waye | Chief Medical Officer | A | Common Stock | 26250 | $0.00 | 26,250.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 122500 | $0.00 | 122,500.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | Chu Yu-Waye | Chief Medical Officer | A | Performance Stock Units (PSUs) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | Ogden Christopher | SVP, Finance and Accounting | A | Stock Option (Right to Buy) | 154000 | $0.00 | 154,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | Ogden Christopher | SVP, Finance and Accounting | A | Common Stock | 40000 | $0.00 | 88,657.0000 | 0 | 82.21% | 0.00% |
| Jan. 18, 2024 | ROWLAND LLOYD A | General Counsel | A | Performance Stock Units (PSUs) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | ROWLAND LLOYD A | General Counsel | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | ROWLAND LLOYD A | General Counsel | A | Common Stock | 25000 | $0.00 | 122,996.0000 | 0 | 25.51% | 0.00% |
| Jan. 18, 2024 | McCarthy Sean A. | CEO | A | Performance Stock Units (PSUs) | 260000 | $0.00 | 260,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | McCarthy Sean A. | CEO | A | Stock Option (Right to Buy) | 420000 | $0.00 | 420,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | McCarthy Sean A. | CEO | A | Common Stock | 90000 | $0.00 | 637,862.0000 | 0 | 16.43% | 0.00% |
| Jan. 18, 2024 | Ogden Christopher | SVP, Finance and Accounting | A | Performance Stock Units (PSUs) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | Landau Jeffrey B | Chief Business Officer | A | Common Stock | 30000 | $0.00 | 124,302.0000 | 0 | 31.81% | 0.00% |
| Jan. 18, 2024 | Landau Jeffrey B | Chief Business Officer | A | Stock Option (Right to Buy) | 140000 | $0.00 | 140,000.0000 | 0 | 9999.99% | 0.00% |